Stock News & Analysis

The EV maker is growing sales faster than most of its big-name peers -- so what's weighing on the stock?

Oil is highly volatile, with focused pure-play drillers likely to benefit most from high oil prices.

ITA offers lower costs and steadier returns, while SHLD delivers higher income but greater volatility. Which strategy fits your portfolio?

Treasuries pay more today, but these three healthcare dividend payers offer something Treasuries can't: growth in both the payout and the stock.

Weak engagement trends are leading investors to hit sell.

This under-the-radar industrial technology stock boasts a Superscore of 74 from our Hidden Gems Primary database, part of The Motley Fool's Moneyball Database system. Here's why.

Nvidia is the chip fund's top position. So where did the rest of the fund's gain come from?

An analyst reiterated his bullish take on the prominent engineering company.

The company extended its existing partnership with a major pharmacy chain.

These stocks are not beneficiaries of the artificial intelligence boom.

GE Areospace's 19% net margin and $7.3B free cash flow contrast sharply with SpaceX's $14B cash burn, yet their valuations tell a starkly different story.

It's leaving the past behind, and investors cheered the move.

Space Exploration Technologies wants to become a semiconductor giant.

One focuses on lunar infrastructure with heavy customer concentration; the other is scaling launch services but carrying an $8 billion acquisition burden.

Taiwan Semiconductor is a reasonably priced AI investment.

AbbVie boasts stronger revenue growth and free cash flow, while Bristol Myers Squibb trades at half the valuation with nearly double the profit margin.

Inflation is running hot, and the Fed is raising interest rates, but consumers aren't likely to pull back on the products these companies sell.

This innovative business is currently in a major transitional period, and the future is unknown.

One is a turnaround story burning cash; the other generated $34.4 billion in free cash flow last year. The valuation gap tells the rest.

JNJ trades at a 28% discount on valuation while LLY's cardiometabolic drugs drive 82% of revenue, each bet carries distinct growth and concentration risks.